William Blair Investment Management LLC Buys 269,896 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

William Blair Investment Management LLC lifted its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 16.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,944,695 shares of the biotechnology company's stock after purchasing an additional 269,896 shares during the period. William Blair Investment Management LLC owned approximately 3.06% of Blueprint Medicines worth $169,616,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of BPMC. Quarry LP acquired a new position in Blueprint Medicines during the third quarter valued at $32,000. R Squared Ltd acquired a new position in shares of Blueprint Medicines in the 4th quarter valued at about $51,000. Asset Management One Co. Ltd. acquired a new position in shares of Blueprint Medicines in the 4th quarter valued at about $88,000. Van ECK Associates Corp lifted its position in shares of Blueprint Medicines by 48.2% in the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock worth $97,000 after purchasing an additional 363 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Blueprint Medicines during the third quarter worth approximately $108,000.

Insider Transactions at Blueprint Medicines

In related news, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $110.14, for a total transaction of $250,458.36. Following the completion of the transaction, the chief operating officer now owns 67,109 shares in the company, valued at approximately $7,391,385.26. The trade was a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ariel Hurley sold 3,203 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the sale, the insider now owns 18,270 shares in the company, valued at approximately $1,692,167.40. This trade represents a 14.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,334 shares of company stock worth $3,103,512 in the last three months. Insiders own 4.21% of the company's stock.

Remove Ads

Blueprint Medicines Trading Up 0.3 %

Shares of NASDAQ BPMC traded up $0.25 during midday trading on Friday, hitting $88.72. The stock had a trading volume of 1,840,670 shares, compared to its average volume of 710,609. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. Blueprint Medicines Co. has a fifty-two week low of $80.68 and a fifty-two week high of $121.90. The firm has a market cap of $5.67 billion, a P/E ratio of -82.15 and a beta of 0.58. The company's 50-day simple moving average is $99.45 and its 200 day simple moving average is $93.92.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Research analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on BPMC shares. HC Wainwright reaffirmed a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Stephens reissued an "overweight" rating and set a $140.00 target price on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Piper Sandler raised their price target on Blueprint Medicines from $109.00 to $119.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Wolfe Research began coverage on Blueprint Medicines in a research note on Tuesday. They set an "outperform" rating for the company. Finally, Morgan Stanley started coverage on Blueprint Medicines in a research report on Thursday. They issued an "equal weight" rating and a $100.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Blueprint Medicines currently has an average rating of "Moderate Buy" and a consensus target price of $124.95.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.